| http://purl.uniprot.org/citations/19461159 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/19461159 | http://www.w3.org/2000/01/rdf-schema#comment | "Nesfatin/nucleobindin 2 (NUCB2) is expressed in the appetite-control hypothalamic nuclei and brainstem nuclei. Nesfatin/NUCB2 expression in the paraventricular nucleus of the hypothalamus was modulated by starvation and refeeding. Intracerebroventricular administration of nesfatin-1 dose-dependently inhibited food intake for 6 hours in male Wistar and leptin resistant, Zucker fatty rats. Intraperitoneal administration of nesfatin-1 and its mid-segment (M30) dosedependentlyinhibited food intake for 3 hours in male ICR mice. Intraperitoneal administration of M30 also decreased foodintake in leptin-resistant, genetically obese (ob/ob), diabetic (db/db) mice and mice fed a 45% high fat diet for 28 days. Intraperitoneal administration of M30 increased proopiomelanocortin and cocaine- and amphetamine-related peptide mRNA expression in the nucleus of the solitary tract of mice. In addition, intranasal administration of nesfatin-1 significantly inhibited food intake for 6 hours in male Wistar rats. We summarize recent observations about nesfatin-1, and attempt to present future direction of nesfatin-1 research for developing a new anti-obesity treatment."xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.org/dc/terms/identifier | "doi:10.1507/endocrj.k09e-117"xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/author | "Mori M."xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/author | "Okada S."xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/author | "Shimizu H."xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/author | "Oh-I S."xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/date | "2009"xsd:gYear |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/name | "Endocr J"xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/pages | "537-543"xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/title | "Nesfatin-1: an overview and future clinical application."xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://purl.uniprot.org/core/volume | "56"xsd:string |
| http://purl.uniprot.org/citations/19461159 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/19461159 |
| http://purl.uniprot.org/citations/19461159 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/19461159 |
| http://purl.uniprot.org/uniprot/#_Q3UKN6-mappedCitation-19461159 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/19461159 |
| http://purl.uniprot.org/uniprot/#_P81117-mappedCitation-19461159 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/19461159 |
| http://purl.uniprot.org/uniprot/#_Q3TV28-mappedCitation-19461159 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/19461159 |
| http://purl.uniprot.org/uniprot/Q3UKN6 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/19461159 |
| http://purl.uniprot.org/uniprot/P81117 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/19461159 |
| http://purl.uniprot.org/uniprot/Q3TV28 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/19461159 |